David Baltimore - Jan 30, 2025 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 30, 2025
Transactions value $
$20,787
Form type
4
Date filed
1/31/2025, 05:00 PM
Previous filing
May 21, 2024
Next filing
Apr 30, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Purchase $20.8K +19.6K +766.31% $1.06 22.2K Jan 30, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average purchase price for the transaction reported was $1.06, and the range of prices were between $0.97 and $1.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided.